Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack breakthrough: drugs may beat stents for mild blockages

NCT ID NCT07567625

Disease control Sponsor: Harbin Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study looks at whether heart attack patients with mild artery narrowing can be treated with medication alone instead of getting a stent. About 2,000 people will be randomly assigned to either standard medication or medication plus a stent. The goal is to see if medication alone is just as good at preventing future heart problems, like another heart attack or the need for another procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female patients aged ≥18 years and ≤75 years; 2. Diagnosis of type 1 AMI, including STEMI (onset \<24 hours or 7-14 days) or NSTEMI; 3. After coronary angiography (CAG) ± thrombus aspiration, TIMI flow in the culprit vessel is restored to grade 3 and maintained for at least 5 minutes, with diameter stenosis (DS) \<70% at the culprit lesion (QCA); 4. Reference diameter of the culprit lesion \>2.5 mm and ≤4.0 mm; 5. Patients or a legally authorized representative must provide written Informed Consent prior to any study related procedure. Exclusion Criteria: 1.Clinical exclusion criteria: 1. Severe cardiac dysfunction (Killip/NYHA class ≥ 3) or LVEF \< 30%; 2. Cardiopulmonary resuscitation (CPR) performed at the onset of AMI; 3. Persistent hemodynamic or cardiac electrical instability after TIMI flow restoration; 4. Contraindication to antithrombotic drugs, or concurrent hemorrhagic diseases such as peptic ulcer or coagulation disorders; 5. Contraindication to contrast; 6. Severe renal dysfunction \[defined as eGFR ≤30 ml/min/1.73m² or Scr ≥2.0 mg/dL\] without regular dialysis (patients with chronic renal insufficiency on regular dialysis may be considered for enrollment); 7. Active liver disease, defined as known infectious, neoplastic, or metabolic liver lesions, with ALT and AST \>3× upper limit of normal (ULN); 8. Previous history of CABG or PCI for the culprit lesion; 9. Patients with other concurrent severe diseases and an expected life expectancy of \<1 year; 10. Pregnant or lactating women. Women of childbearing potential must use effective contraceptive measures during the study treatment period; 11. Inability to comply with the study protocol or other conditions deemed unsuitable for study participation by the investigator. 2.Imaging exclusion criteria: 1. Non-culprit lesion with DS ≥70% or planned revascularization; 2. Left main coronary artery lesion with DS ≥50%; 3. Culprit lesion is a true bifurcation lesion requiring a two-stent strategy; 4. Long lesion (planned stent length \>60 mm); 5. Culprit lesion with dissection, false lumen, or other conditions necessitating stent implantation; 6. Target lesion has undergone pre-treatment (such as balloon dilation, rotational atherectomy, etc.). 3.Functional sub study: 1. Individuals who are allergic to adenosine triphosphate (ATP) or any component in its preparations; 2. Second and third degree atrioventricular block, sick sinus syndrome (without artificial pacemaker protectors); 3. Patients with bronchial asthma.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction (AMI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction (AMI) Non-ST-segment elevation myocardial infarction(nstemi) ST-segment elevation myocardial infarction (stemi)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    48 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Luhe Hospital Affiliated to Capital Medical University

    NOT_YET_RECRUITING

    Beijing, China

  • Cangzhou Central Hospital

    NOT_YET_RECRUITING

    Cangzhou, China

  • Central Hospital of Jiamusi City

    NOT_YET_RECRUITING

    Jiamusi, China

  • Chengde Medical College Affiliated Hospital

    NOT_YET_RECRUITING

    Chengde, China

  • China-Japan Union Hospital of Jilin University

    NOT_YET_RECRUITING

    Jilin City, China

  • Daqing Oilfield General Hospital

    NOT_YET_RECRUITING

    Daqing, China

  • Fuwai Hospital, Chinese Academy of Medical Sciences

    NOT_YET_RECRUITING

    Beijing, China

  • Fuwai Huazhong Cardiovascular Hospital

    NOT_YET_RECRUITING

    Zhengzhou, China

  • General Hospital of Taiyuan Iron and Steel (Group) Co.

    NOT_YET_RECRUITING

    Taiyuan, China

  • General Hospital of Tianjin Medical University

    NOT_YET_RECRUITING

    Tianjin, China

  • Hebei Provincial People's Hospital

    NOT_YET_RECRUITING

    Shijiazhuang, China

  • Jilin Central Hospital

    NOT_YET_RECRUITING

    Jilin City, China

  • Lanzhou University First Hospital

    NOT_YET_RECRUITING

    Lanzhou, China

  • Liaoning Provincial People's Hospital

    NOT_YET_RECRUITING

    Shenyang, China

  • Linyi People's Hospital

    NOT_YET_RECRUITING

    Linyi, China

  • Mudanjiang Cardiovascular Hospital

    NOT_YET_RECRUITING

    Mudanjiang, China

  • People's Hospital of Xinjiang Uygur Autonomous Region

    NOT_YET_RECRUITING

    Xinjiang, China

  • Qiqihar First Hospital

    NOT_YET_RECRUITING

    Qiqihar, China

  • Shandong Provincial Hospital

    NOT_YET_RECRUITING

    Jinan, China

  • Shanxi Provincial Cardiovascular Hospital

    NOT_YET_RECRUITING

    Taiyuan, China

  • Shengjing Hospital of China Medical University

    NOT_YET_RECRUITING

    Shenyang, China

  • Sichuan Provincial People's Hospital

    NOT_YET_RECRUITING

    Chengdu, China

  • Suihua First Hospital

    NOT_YET_RECRUITING

    Suihua, China

  • TEDA International Cardiovascular Hospital

    NOT_YET_RECRUITING

    Tianjin, China

  • The Affiliated Hospital of Jining Medical University

    NOT_YET_RECRUITING

    Jining, China

  • The Affiliated Hospital of Qingdao University

    NOT_YET_RECRUITING

    Qingdao, China

  • The Central Hospital Affiliated to Dalian University of Technology

    NOT_YET_RECRUITING

    Dalian, China

  • The First Affiliated Hospital of Dalian Medical University

    NOT_YET_RECRUITING

    Dalian, China

  • The First Affiliated Hospital of Jiamusi University

    NOT_YET_RECRUITING

    Jiamusi, China

  • The First Affiliated Hospital of Nanyang Medical College

    NOT_YET_RECRUITING

    Nanyang, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    NOT_YET_RECRUITING

    Xi'an, China

  • The First Affiliated Hospital of Xinjiang Medical University

    NOT_YET_RECRUITING

    Xinjiang, China

  • The First Affiliated Hospital of Zhengzhou University

    NOT_YET_RECRUITING

    Zhengzhou, China

  • The First Hospital of Jilin University

    NOT_YET_RECRUITING

    Jilin City, China

  • The Fourth Affiliated Hospital of China Medical University

    NOT_YET_RECRUITING

    Shenyang, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    NOT_YET_RECRUITING

    Harbin, China

  • The Second Affiliated Hospital of Dalian Medical University

    NOT_YET_RECRUITING

    Dalian, China

  • The Second Affiliated Hospital of Harbin Medical University

    RECRUITING

    Harbin, Heilongjiang, 150086, China

  • The Second Affiliated Hospital of Qiqihar Medical University

    NOT_YET_RECRUITING

    Qiqihar, China

  • The Second Affiliated Hospital of Wenzhou Medical University

    NOT_YET_RECRUITING

    Wenzhou, China

  • The Second Hospital of Hebei Medical University

    NOT_YET_RECRUITING

    Shijia Zhuang, China

  • The Third Affiliated Hospital of Qiqihar Medical University

    NOT_YET_RECRUITING

    Qiqihar, China

  • The Third Xiangya Hospital of Central South University

    NOT_YET_RECRUITING

    Hunan, China

  • Tianjin Chest Hospital

    NOT_YET_RECRUITING

    Tianjin, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    NOT_YET_RECRUITING

    Wuhan, China

  • Wuhan Asia Heart Hospital

    NOT_YET_RECRUITING

    Wuhan, China

  • Yantai Yuhuangding Hospital

    NOT_YET_RECRUITING

    Yantai, China

  • Zunyi Medical University Affiliated Hospital

    NOT_YET_RECRUITING

    Zunyi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.